November 25, 2016 - By Ellis Scott · 0 Comments
The stock of Baxter International Incorporated (NYSE:BAX) registered a decrease of 12.18% in short interest. BAX’s total short interest was 12.72 million shares in November as published by FINRA. Its down 12.18% from 14.49M shares, reported previously. With 4.56 million shares average volume, it will take short sellers 3 days to cover their BAX’s short positions. The short interest to Baxter International Incorporated’s float is 2.59%. About 135,573 shares traded hands. Baxter International Inc (NYSE:BAX) has risen 7.48% since April 22, 2016 and is uptrending. It has outperformed by 2.07% the S&P500.
Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The company has a market cap of $25.66 billion. The Firm operates through two divisions: Hospital Products and Renal. It has a 5.26 P/E ratio. The Company’s Hospital Products business makes IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products.
Insitutional Activity: The institutional sentiment increased to 0.83 in Q2 2016. Its up 0.15, from 0.68 in 2016Q1. The ratio increased, as 75 funds sold all Baxter International Inc shares owned while 363 reduced positions. 67 funds bought stakes while 233 increased positions. They now own 437.24 million shares or 6.33% less from 466.81 million shares in 2016Q1.
Girard Ltd reported 7,719 shares or 0.13% of all its holdings. Us Bancorp De holds 429,671 shares or 0.07% of its portfolio. Leavell Inv Management has 0.1% invested in the company for 14,254 shares. Paradigm Asset Company Limited Liability reported 115,036 shares or 0% of all its holdings. John G Ullman And Incorporated holds 0.1% or 11,074 shares in its portfolio. Stevens Capital Mngmt Lp last reported 0.38% of its portfolio in the stock. Vanguard Grp holds 0.1% or 34.07M shares in its portfolio. Moreover, Horizon Kinetics Ltd Llc has 0.02% invested in Baxter International Inc (NYSE:BAX) for 14,122 shares. Wealthtrust holds 0.01% of its portfolio in Baxter International Inc (NYSE:BAX) for 203 shares. Finemark Bancshares And Tru last reported 0.05% of its portfolio in the stock. Moreover, Ibm Retirement Fund has 0.11% invested in Baxter International Inc (NYSE:BAX) for 65,402 shares. Pure Advsr Inc holds 0.11% or 7,395 shares in its portfolio. Axa has 0.03% invested in the company for 170,406 shares. Veritas Asset Mngmt Ltd Liability Partnership holds 9.13M shares or 4.54% of its portfolio. Amalgamated Retail Bank has invested 0.08% of its portfolio in Baxter International Inc (NYSE:BAX).
Insider Transactions: Since November 18, 2016, the stock had 0 insider purchases, and 1 insider sale for $201,588 net activity. STORM KORNELIS J. had sold 4,280 shares worth $201,588.
Out of 11 analysts covering Baxter International (NYSE:BAX), 5 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 45% are positive. Baxter International has been the topic of 20 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The stock has “Overweight” rating given by Piper Jaffray on Monday, November 16. Barclays Capital initiated the stock with “Overweight” rating in Thursday, September 15 report. The stock of Baxter International Inc (NYSE:BAX) has “Neutral” rating given on Tuesday, September 22 by UBS. The stock of Baxter International Inc (NYSE:BAX) earned “Buy” rating by Evercore on Wednesday, May 4. The stock of Baxter International Inc (NYSE:BAX) earned “Sector Perform” rating by RBC Capital Markets on Wednesday, February 3. The rating was downgraded by Leerink Swann to “Market Perform” on Thursday, July 30. The stock has “Neutral” rating given by Credit Suisse on Monday, August 10. The company was upgraded on Thursday, April 14 by Piper Jaffray. Leerink Swann maintained Baxter International Inc (NYSE:BAX) rating on Wednesday, October 28. Leerink Swann has “Market Perform” rating and $42 price target. On Tuesday, August 11 the stock rating was maintained by Barclays Capital with “Overweight”.
Baxter International Inc., incorporated on October 19, 1931, through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Firm operates through two divisions: Hospital Products and Renal. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision. The Firm makes products in approximately 30 countries and sells them in approximately 120 countries.
Another recent and important Baxter International Inc (NYSE:BAX) news was published by Fool.com which published an article titled: “Baxter International Inc Gets More Efficient” on October 26, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott